Advertisement
Table 2 PTEN status of various cancer types as adapted from reference [133]
| Cancer type | PTEN status | References |
|---|---|---|
| Head and neck cancer | - Decreased PTEN expression in 30% of patients | [154] |
| Glioblastoma | - Loss of heterozygosity of PTEN in 60%–80% of patients | [155] |
| - PTEN mutations in up to 40% of patients | ||
| Breast cancer | - PTEN mutations in 3% of patients | [156, 157] |
| - Loss of PTEN protein in 30% of patients | ||
| Ovarian cancer | - Loss of heterozygosity of PTEN in 45% of endometrioid carcinoma of the ovary | [158] |
| Non-small cell lung cancers | - Loss of PTEN protein expression in 75% of patients | [159] |
| Endometrial cancer | - Mutation or reduction of heterozygosity in 55% of patients | [160] |
| Colorectal cancer | - Loss of PTEN protein expression in 20%-40% of patients | [161] |
| Prostate cancer | - PTEN mutations in 15% of primary tumours, 20% of localised tumours and 50% of hormone-refractory cancer patients | [162] |
